2'-carboethoxy-3-(2-methylphenyl)propiophenone, 97.0%, 1g

(2E)-1-(2,5-dimethoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one, 95.0%, 10g

Isobenzofuran-1(3H)-one, 95.0%, 100g

3,6-Bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine, 97.0%, 10g

(3aR,7aR)-1,3-Di-o-tolyl-3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazol-3-ium tetrafluoroborate, 98%, 100mg

6-BROMO-[1,2,4]TRIAZOLO[1,5-B]PYRIDAZIN-2-AMINE, 95.0%, 1g

Microliter syringe GASTIGHT® series 1700 Point type 2, 250 µl, 1725 RN, 1 piece

4-Phenyl-[1,2,3]thiadiazole-5-carboxylic acid ethyl ester, 95.0%, 1g

Warning symbol according to ISO 7010 Individual label, Non-ionizing radiation, Side length 100 mm, 1 piece

6-FLUORO-2-AZASPIRO[3.4]OCTANE HCL, 95%, 1g

4-Methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole, 98%, 250mg

4-Chlorothiophenol, 97.0%, 500g

1,2-Di(thiophen-2-yl)disulfane, 97.0%, 250mg